Instead, TNBC tumor genomics varies, resulting in proposed subclassifications within the TNBC subtype, and can be characterized by loss-of-function mutations in tumor suppressors such as BRCA1/2 or TP53 [10]. This evidence concerns the gene BRCA1 and neoplasm.